SCHEMBL4411512

SCHEMBL4411512

O=C(NNc1ccc2ccccc2n1)c1ccccn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.60
RAB9A P51151 8/20 0.58
NPC1 O15118 7/20 0.58
KDM4E B2RXH2 6/20 0.58
SMN1; SMN2 Q16637 6/20 0.58
ALDH1A1 P00352 3/20 0.58
TP53 P04637 3/20 0.58
NFKB1 P19838 3/20 0.58
NFKB2 Q00653 3/20 0.58
RELA Q04206 3/20 0.58
TSHR P16473 1/20 0.58
PAX8 Q06710 1/20 0.54
TLR7 Q9NYK1 4/20 0.48
HTT P42858 4/20 0.48
LMNA P02545 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
GAA P10253 1/20 0.47
HCRTR1 O43613 1/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19089786 0.84 KDM5A (0.45) KDM5ARAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL23388826 0.80 SMN1; SMN2 (0.61) KDM5ARAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL29995352 0.80 SMN1; SMN2 (0.61) KDM5ARAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL1147702 0.76 KDM4E (0.73) KDM5ARAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL10062372 0.75 KDM5A (1.00) KDM5ARAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL4414176 0.75 KDM4E (0.59) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL15032175 0.75 KDM5A (0.48) KDM5ARAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL15130317 0.74 RAB9A (0.69) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL28209398 0.74 ALDH1A1 (0.56) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL3860280 0.74 RAB9A (1.00) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11839617-B2 Theramutein modulators HMI Medical Innovations, LLC (US) 2023-12-12 US disclosed
US-20210215671-A1 COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS HMI Medical Innovations, LLC 2021-07-15 US disclosed
US-20210215670-A1 COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS HMI Medical Innovations, LLC 2021-07-15 US disclosed
US-10955408-B2 Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators HMI Medical Innovations, LLC (US) 2021-03-23 US disclosed
US-20210015825-A1 THERAMUTEIN MODULATORS HMI Medical Innovations, LLC 2021-01-21 US disclosed
US-20210008077-A1 THERAMUTEIN MODULATORS HMI Medical Innovations, LLC 2021-01-14 US disclosed
US-10806738-B2 Theramutein modulators HMI Medical Innovations, LLC (US) 2020-10-20 US disclosed
US-20200046718-A1 THERAMUTEIN MODULATORS HMI Medical Innovations, LLC 2020-02-13 US disclosed
US-20200049693-A1 COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS HMI Medical Innovations, LLC 2020-02-13 US disclosed
US-10473643-B2 Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators HMI Medical Innovations, LLC (US) 2019-11-12 US disclosed
US-20100016298-A1 Theramutein modulators HOUSEY GERAD M 2010-01-21 US disclosed
US-20090275070-A1 Compounds and Methods of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators HOUSEY GERARD M 2009-11-05 US disclosed
US-20090275070-A1 Compounds and Methods of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators HOUSEY GERARD M 2009-11-05 US disclosed
US-20080269262-A1 Blocking or activation of endogenous proteins variations rncoded by mutated gees HMI MEDICAL INNOVATIONS, LLC. 2008-10-30 US disclosed
US-20080269262-A1 Blocking or activation of endogenous proteins variations rncoded by mutated gees HMI MEDICAL INNOVATIONS, LLC. 2008-10-30 US disclosed
WO-2008091681-A2 THERAMUTEIN MODULATORS HOUSEY GERARD M (US) 2008-07-31 WO disclosed
WO-2007062213-A2 COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS HOUSEY PHARMACEUTICALS INC (US) 2007-05-31 WO disclosed
US-20070111199-A1 Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators HMI Medical Innovations, LLC 2007-05-17 US disclosed
US-20070111199-A1 Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators HMI Medical Innovations, LLC 2007-05-17 US disclosed
WO-2007037898-A2 THERAMUTEIN MODULATORS HOUSEY PHARMACEUTICALS INC (US) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210008077-A1 THERAMUTEIN MODULATORS TSG101, SERPINE1, PLAUR KDM5A 4434/4885RAB9A 2031/4885NPC1 4410/4885
US-20100016298-A1 Theramutein modulators TSG101, SERPINE1, PLAUR KDM5A 4434/4885RAB9A 2031/4885NPC1 4410/4885
US-20210015825-A1 THERAMUTEIN MODULATORS TSG101, SERPINE1, PLAUR KDM5A 4434/4885RAB9A 2031/4885NPC1 4410/4885
US-10806738-B2 Theramutein modulators TSG101, SERPINE1, PLAUR KDM5A 4434/4885RAB9A 2031/4885NPC1 4410/4885
US-11839617-B2 Theramutein modulators TSG101, SERPINE1, PLAUR KDM5A 4434/4885RAB9A 2031/4885NPC1 4410/4885
US-20200046718-A1 THERAMUTEIN MODULATORS TSG101, SERPINE1, PLAUR KDM5A 4434/4885RAB9A 2031/4885NPC1 4410/4885
US-20080269262-A1 Blocking or activation of endogenous proteins variations rncoded by mutated gees SERBP1, SERPINA6, UBE2V1 KDM5A 3794/4885RAB9A 1721/4885NPC1 4244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.